Stockscreener 앱 받기
6.68
3.33%
-0.23
Eupraxia Pharmaceuticals Inc 주식(EPRX)의 최신 뉴스
Why Eupraxia Pharmaceuticals Inc stock is tanking today - Wealth Awesome
Eupraxia Pharmaceuticals Adds Veteran Drug Developers to Board as Pipeline Advances - TipRanks
Eupraxia Pharmaceuticals (EPRX) adds three drug development and commercialization experts to board - Stock Titan
Eupraxia Pharmaceuticals appoints three directors to board - Investing.com
Eupraxia Pharmaceuticals Strengthens Board with Three Industry Leaders in Drug Development and Commercialization - Investing News Network
Eupraxia Pharmaceuticals appoints three directors to board By Investing.com - Investing.com Australia
EPRX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
EPRX Technical Analysis & ETF Price Forecast - Intellectia AI
EPRX Technical Analysis & Stock Price Forecast - Intellectia AI
A3EGRS Forecast — Price Target — Prediction for 2027 - TradingView
Eupraxia Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:EPRX) - TradingView
EPRX Forecast — Price Target — Prediction for 2027 - TradingView
Oppenheimer initiates Eupraxia stock with Outperform rating By Investing.com - Investing.com Nigeria
Eupraxia Pharmaceuticals, Inc. Actuals & Estimates (FWB:X43) - TradingView
Oppenheimer Initiates Eupraxia Pharmaceuticals(EPRX.US) With Buy Rating, Announces Target Price $17 - Moomoo
X43 Forecast — Price Target — Prediction for 2027 - TradingView
Price to sales forward of Eupraxia Pharmaceuticals, Inc. – TSX:EPRX - TradingView
Price to earnings forward of Eupraxia Pharmaceuticals, Inc. – TSX:EPRX - TradingView
Enterprise value to EBITDA forward of Eupraxia Pharmaceuticals, Inc. – TSX:EPRX - TradingView
Eupraxia Pharmaceuticals (EPRX) Slips 2.19% as Stock Tests Key Support at $5.94Shakeout Pattern - dars.gov.et
Eupraxia Pharmaceuticals (EPRX) Stock Analysis Report | Financials & Insights - Benzinga
Why Eupraxia Pharmaceuticals Inc stock is rising today - Wealth Awesome
Eupraxia Pharmaceuticals Shareholders Back Board Slate and Auditor at June 18 AGM - TipRanks
Form 6K Eupraxia Pharmaceuticals Inc For: 22 June By Investing.com - Investing.com South Africa
Strong support as Eupraxia (NASDAQ: EPRX) shareholders elect seven directors, renew KPMG - Stock Titan
Eupraxia Pharmaceuticals elects all seven board nominees and reappoints KPMG as auditor at AGM. - Pluang
Eupraxia Pharmaceuticals Announces Voting Results from Annual General Meeting of Shareholders - The Manila Times
Eupraxia shareholders back all 7 directors at annual meeting - Stock Titan
Eupraxia Pharmaceuticals Announces Voting Results from Annual General Meeting of Shareholders - GlobeNewswire Inc.
Why Eupraxia Pharmaceuticals Inc stock is sliding today - Wealth Awesome
Eupraxia Pharmaceuticals Inc (EPRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Eupraxia Pharmaceuticals Inc (EPRX) Institutional Confidence - TradingKey
Eupraxia Pharmaceuticals Inc (EPRX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Eupraxia Pharmaceuticals Inc (EPRX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Eupraxia Pharmaceuticals Inc (EPRX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Eupraxia Pharmaceuticals Inc - TradingKey
Eupraxia Pharmaceuticals Inc (EPRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Eupraxia Pharmaceuticals Inc (EPRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Why Eupraxia Pharmaceuticals Inc stock is skyrocketing today - Wealth Awesome
Why Eupraxia Pharmaceuticals Inc stock is plummeting today - Wealth Awesome
Eupraxia Pharmaceuticals Inc (EPRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
This SailPoint analyst begins coverage on a bullish note; here are top 3 initiations for Thursday - MSN
Eupraxia Pharmaceuticals Q1 2026 Earnings: Narrow Loss Misses Estimates as Clinical Pipeline AdvancesNext Quarter Guidance - dars.gov.et
Eupraxia Pharmaceuticals, Inc. Financial Disclosures & Filings - TradingView
EPRX Q1 2026 Earnings: EPS Misses Estimates as Clinical-Stage Biotech Reports No Revenue - dars.gov.et
EPRX Q1 2026 Earnings: Wider-Than-Expected Loss Weighs on SharesDebt Analysis Report - newsline.com
Osteoarthritis Market Gains Momentum with Expanding Pipeline and Investment Potential by 2036 – DelveInsight | Merck KGaA, Peptinov, LG Chem, Akan Bioscience, BioTissue,Inc., Eupraxia Pharma - Barchart
Eupraxia Pharmaceuticals Confirms Mailing of 2026 Proxy Materials to Shareholders - The Globe and Mail
Eupraxia Pharmaceuticals Sets June 18, 2026 Virtual AGM and Files May Form 6-K - TipRanks
Eupraxia (EPRX) details 2026 virtual AGM, board nominees and pay plan - Stock Titan
Eupraxia Pharmaceuticals (EPRX) confirms mailing of proxy materials to holders - Stock Titan
EPRX Q1 2026 Earnings: Wider-Than-Expected Loss as Pre-Revenue Biotech Advances PipelineEarnings Revision Downgrade - The Legal Advocate
Eupraxia Pharmaceuticals to Showcase Pipeline at Jefferies Global Healthcare Conference - TipRanks
Eupraxia Pharmaceuticals (EPRX) to present at Jefferies Global Healthcare Conference - Stock Titan
(EPRX.WT.A) Equity Market Report - Stock Traders Daily
Eupraxia Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference - NorthBayNipissing.com
Biotech Eupraxia heads to New York for Jefferies health conference June 3 - Stock Titan
EPRXEupraxia Pharmaceuticals Inc Stock Price and Quote - Finviz
Eupraxia Pharmaceuticals (EPRX) Rises 2.3% as Stock Approaches Key Resistance LevelDay Trade Opportunities - newsline.com
Eupraxia Pharmaceuticals (EPRX) Q1 2026 Earnings: Clinical Progress Overshadows Slight EPS MissLong-Term Guidance - Newser
Stifel Maintains Eupraxia Pharmaceuticals(EPRX.US) With Buy Rating, Maintains Target Price $25 - Moomoo
Eupraxia Pharmaceuticals (EPRX) Q1 2026 Miss: What Went WrongCommunity Exit Signals - Newser
Stifel Initiates Eupraxia Pharmaceuticals at Buy With CA$34.37 Price Target - Moomoo
This SailPoint Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday - Benzinga
2.64%
자본화:
|
볼륨(24시간):